A dangerous animal tranquilizer known as “tranq dope” has made its way into the UK drug market, causing concern among health officials and law enforcement. Xylazine, the powerful sedative, has already been linked to 11 deaths in the country, with users experiencing severe side effects such as airway compromise and skin ulcers that can lead to limb amputation.
A recent study published in the journal Addiction, led by researchers from King’s College London, highlighted the growing presence of xylazine in various illicit substances, including counterfeit prescription medication tablets, THC vapes, and cocaine. The study found 35 cases of xylazine across England, Scotland, and Wales, with 16 biological samples testing positive for the drug, including 11 individuals who had died.
Dr. Caroline Copeland, senior author of the study, expressed alarm at the widespread availability of xylazine in the UK’s drug market, emphasizing the need for preventive measures to curb its use. The government has announced plans to classify xylazine as a Class C drug, with penalties of up to 14 years in prison for those caught supplying the substance.
The emergence of xylazine in the UK highlights the evolving landscape of drug use and the challenges faced by authorities in combating the spread of dangerous substances. Health officials and law enforcement agencies are working together to address the threat posed by xylazine and protect the public from its harmful effects.